E-GEOD-2251 - Transcription profiling of human breast cancer cells expressing ERalpha and treated with 17beta-estradiol
Submitted on 7 February 2005, released on 25 August 2007, last updated on 27 March 2012
Gene expression changes caused by estrogen treatment of breast cancer cells that re-express ERalpha was investigated by infecting ER-negative MDA-MB-231 breast cancer cells for 24 h with recombinant adenovirus encoding full-length human ERalpha (Ad-ERalpha) or control vector (Ad-LacZ), and treating them with 0·01% ethanol (vehicle control) or 10-8 M 17beta-estradiol (E2). After 48 h of treatment, total RNA was isolated and used for transcript profiling on Affymetrix GeneChips. Three independent biological replicates of this experiment were carried out.
transcription profiling by array, co-expression, compound treatment, genetic modification
Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes. J G Moggs, T C Murphy, F L Lim, D J Moore, R Stuckey, K Antrobus, I Kimber, G Orphanides. J Mol Endocrinol 34(2):535-51 (2005)